Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy ...

If confirmed by the Senate, Schwartz could finally fill a void for an agency that’s cycled through multiple leaders over the last year.

The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes.

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...

The estimated 6,000 women a day who reach menopause experience it differently. Some have debilitating, vasomotor symptoms ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, ...

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...